Switching to adalimumab is effective in a case of neuro-Behcet's disease refractory to infliximab.
Leccese
Pietro
P
D'Angelo
Salvatore
S
Angela
Padula
P
Coniglio
Gabriella
G
Olivieri
Ignazio
I
D000068879:Adalimumab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001528:Behcet Syndrome / Q000188:drug therapy*; D006801:Humans; D000069285:Infliximab; D008297:Male; D017211:Treatment Failure; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab